-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive ImpairmentDrug Details:Sodium...
-
Product Insights
Amyotrophic Lateral Sclerosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Amyotrophic Lateral Sclerosis Clinical Trials Market Report Overview In total there were 694 clinical trials conducted on Amyotrophic Lateral Sclerosis, as of April 2023.The Amyotrophic Lateral Sclerosis clinical trial market research report provides an overview of the Amyotrophic Lateral Sclerosis clinical trials scenario. The report provides top-line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage...
-
Company Profile
Amylyx Pharmaceuticals Inc – Company Profile
Amylyx Pharmaceuticals Inc (Amylyx) discovers and develops pharmaceutical products for the treatment of neurodegenerative diseases. The company is investigating AMX0035, an oral coformulation of sodium phenylbutyrate and taurursodiol compounds to treat amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Wolfram syndrome. Its product candidate focuses on reducing neuronal death by mitigating endoplasmic reticulum stress and mitochondrial dysfunction. Amylyx seeks to work in collaboration with researchers and biotechnology companies to develop its products. The company has operational presence in Calgary, Canada and...
Add to Basket -
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Alzheimer is a progressive neurologic disorder beginning with mild memory loss. It could possibly lead to a loss of the ability to carry on a conversation and respond to the environment. The Alzheimer pipeline market research report provides comprehensive information about the Alzheimer pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Net Present Value Model: Albrioza
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Albrioza Drug Details Sodium phenylbutyrate and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (sodium phenylbutyrate + taurursodiol)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (sodium phenylbutyrate + taurursodiol) Drug Details Sodium phenylbutyrate and Taurursodiol (Albrioza, Relyvrio) is a...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Friedreich Ataxia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Friedreich Ataxia Drugs in Development Report Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Its signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...